News

Ideas That Generate Results

The global market for oncology drugs, including supportive care, reached US$ 91 Billion approximately in 2013 growing at a CAGR of nearly 5%, up from US$ 72 Billion in 2008. The modest rate reflects a lack of breakthrough therapies for very large patient populations, patent expiries, reductions in the use of supportive care medicines and stronger payer management.

On the other hand, the cancer generics market is anticipated to grow at a CAGR of around 12% during 2013-2018. All classes of drugs are set to enjoy significant growth, although in some cases, it is highly dependent on the finalization and implementation of an explicit regulatory framework for the approval of generics. The market for cancer generics will be driven by increasing prevalence of cancers, growth in emerging pharmaceutical markets, and technological advancements with stress on target therapies.

Research Analysis & Highlights

Holistically, our latest research report "Global Cancer Generics Market Outlook 2018", elicits the global oncology market and global caner generics market. Cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to the major indications is also discussed in depth, emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.

Moreover, the dossier also contains the analysis of the top notch global cancer generics manufacturers. On the holistic basis, the report is primarily inclined towards the in-depth study of global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.

Some of the key findings of the report are:

            - Increasing cancer incidences back the growth of the oncology generics market
            - Recent launch of cancer generic drugs
            - US: the highest share claimer in the global oncology market

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM704.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm